Locally Advanced or Metastatic Prostate Cancer.NCT00733213
Depiction of Prostate Cancer Treatment Alternatives in Greece
An observational study of Locally Advanced or Metastatic Prostate Cancer., run by AstraZeneca at 4 sites in Greece.
Trial summary
A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Locally Advanced or Metastatic Prostate Cancer.
- How many people
- 310 participants
- Where
- 4 sitesGreece
- Study dates
- Jan 2008to Mar 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer
Who may be able to join
- Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
- Patients that received Hormonal therapy.
Who cannot join
- Males that are aged less than 18 years
Trial locations and contacts
4 sites in 1 country.
Greece4 sites
Research Site
Athens
Research Site
Karditsa
Research Site
Serres
Research Site
Xsanthi
About this study
A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.
- Target Group: Patients with locally advanced or metastatic prostate cancer.
- The first 10 consecutive patients records that meet the entry criteria.
- Keywords
- Prostate Cancer, Treatment alternatives, Metastasis
- Medical subject headings
- Prostatic Neoplasms, Neoplasm Metastasis
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients treated by each treatment alternative.
Measured: Between 2002 - 2008
Secondary outcomes (1)
To depict sociodemographic characteristics and comorbidities.
Measured: Between 2002 - 2008
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2008 (estimated)
- Study startJan 2008
- Study completionMar 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced or Metastatic Prostate Cancer.Studies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 310 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Panagiotis Pontikis, MD, Study director, AstraZeneca Greece
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00733213
- Sponsor's protocol ID
- NIS-OGR-DUM-2007/1
- Status last verified
- Oct 2009
- First submitted
- 8 Aug 2008
- Last updated
- 14 Oct 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Depiction of Prostate Cancer Treatment Alternatives in Greece
- ClinicalTrials.gov ID
- NCT00733213
- Acronym / sponsor ID
- NIS-OGR-DUM-2007/1
- Keywords
- Prostate Cancer, Treatment alternatives, Metastasis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 310 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Jan 2008
- Study completion
- Mar 2009 (actual)
- First posted
- 12 Aug 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.
- Target Group: Patients with locally advanced or metastatic prostate cancer.
- The first 10 consecutive patients records that meet the entry criteria.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer
Key inclusion criteria (2 listed)
- Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
- Patients that received Hormonal therapy.
Key exclusion criteria (1 listed)
- Males that are aged less than 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of patients treated by each treatment alternative.
Time frame: Between 2002 - 2008
1 secondary outcome
To depict sociodemographic characteristics and comorbidities.
Time frame: Between 2002 - 2008
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2009.
Related trials for Locally Advanced or Metastatic Prostate Cancer.
RecruitingPhase 2
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma
RecruitingPhase 1
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
RecruitingPhase 1/2
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Advanced Solid Tumor, Melanoma
RecruitingPhase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Panagiotis Pontikis, MD study director
AstraZeneca Greece
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Locally Advanced or Metastatic Prostate Cancer., run by AstraZeneca at 4 sites in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Oct 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients treated by each treatment alternative. (time frame: Between 2002 - 2008). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2009.